ANDARIX Pharmaceuticals, a clinical stage company developing a targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the World Orphan Drug Conference in Washington, DC on April 23, 2015. Conference location and agenda information are available at the World Orphan Drug Congress. Andarix’ lead development candidate Tozaride was granted Orphan designation by the by the FDA Office of Orphan Products Development in July 2014 and is being studied in the orphan indications of small cell lung cancer and pancreatic cancer.
Lung cancer is the leading cause of cancer mortality in the United States for both men and women. In 2014, there were an estimated 221,200 new diagnoses of lung cancer including about 40,000 diagnoses of small cell lung cancer. Pancreatic cancer is responsible for significant cancer mortality in the United States, with over 50,000 new diagnoses of pancreatic cancer and over 50,000 deaths attributable to this disease annually.
Tozaride is a novel, best-in-class therapy for lung and other cancers based on the radio-labeled somatostatin peptide Tozaride. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s clinical stage development candidates are based on its proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, pancreatic and neuroendocrine cancers. To learn more about Andarix, please visit www.andarix.com.